In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kyphon: A Trial Balloon Succeeds in Spine

Executive Summary

Until now, most spine surgeons wouldn't even treat osteoporotic fractures of the spine, referring such patients to medical management. But using technology borrowed from balloon angioplasty, Kyphon has developed instrumentation that represents a new clinical approach to this serious problem. As with most device companies, regulatory issues and reimbursement have been a challenge, as have comparisons with another spinal procedure, vertebroplasty.
Advertisement

Related Content

NEJM Studies Continue to Haunt Vertebroplasty Companies
CareFusion Makes Its First Steps Count
Vexim SAS
Dynamic Stabilization Rocks Spine
TranS1:Transcending the Surgeon/Rep/Relationship
Kyphon's Move Into the Mainstream
ArthroCare's Three-Pronged Spine Play
Archus Orthopedics Inc.
Jumping on the Vertebroplasty Bandwagon
Vertebroplasty: Dangerous Learning Curve

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel